ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : Industry : Genentech


Include trials that are no longer recruiting patients.

48 studies were found.
1.RecruitingAvastin With or Without Erlotinib for Treatment of Metastatic Renal Cell Carcinoma
Condition: Renal Cell Cancer
2.RecruitingAvastin/Placebo + Tarceva or Taxotere for Second-line Advanced Non-small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Adenocarcinoma; Carcinoma, Large Cell
3.No longer recruitingChemotherapy With or Without Monoclonal Antibody in Treating Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer
4.No longer recruitingCombination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Conditions: Stage IV rectal cancer; stage IV colon cancer
5.No longer recruitingCombination Chemotherapy With or Without Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer
6.No longer recruitingEfficacy and Safety Study of OSI-774 (Erlotinib) to Treat Advanced Lung Cancer
Condition: Lung Cancer
7.No longer recruitingEfficacy and Safety Study of rhuFab V2 (Ranibizumab) to Treat Age-Related Macular Degeneration
Condition: Age-Related Maculopathy
8.TerminatedEfficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Condition: Renal Cell Cancer
9.No longer recruitingEfficacy and Safety Study of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
10.RecruitingErlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small Cell Lung
11.No longer recruitingErlotinib in Treating Women With Locally Advanced or Metastatic Breast Cancer
Conditions: stage IIIB breast cancer; stage IIIA breast cancer; stage IV breast cancer; recurrent breast cancer
12.RecruitingEvaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Condition: Breast Cancer
13.RecruitingAn Evaluation of the Safety and Efficacy of Ranibizumab in Patients with Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
14.No longer recruitingExtension Study of rhuFab V2 in Subjects with Neovascular Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
15.CompletedGrowth Hormone Use in Cystic Fibrosis - a Multicenter Study
Condition: Cystic Fibrosis
16.No longer recruitingMonoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Conditions: Stage IV rectal cancer; stage IV colon cancer
17.CompletedA Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original study extended ONLY for patients previously enrolled on VEU 009)
Condition: HIV Infections
18.CompletedA Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
Condition: HIV Infections
19.CompletedA Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients with HIV-Associated Immune Thrombocytopenic Purpura
Conditions: Immune thrombocytopenic purpura ( ITP ); HIV Infections
20.CompletedA Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
Condition: HIV Infections
21.CompletedA Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study extended ONLY for subjects who have previously received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover study)
Condition: HIV Infections
22.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
Condition: HIV Infections
23.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
Condition: HIV Infections
24.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns
Conditions: HIV Infections; Pregnancy
25.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
Condition: HIV Infections
26.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex
Condition: HIV Infections
27.CompletedA Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4-Immunoglobulin G (rCD4-IgG) Administered by Intravenous Bolus Injection in Combination With Oral Zidovudine in Patients With AIDS and AIDS-Related Complex
Condition: HIV Infections
28.No longer recruitingA Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections; HIV Seronegativity
29.CompletedPhase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children
Condition: HIV Infections
30.CompletedA Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Condition: HIV Infections
31.CompletedA Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
32.CompletedA Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
Condition: HIV Infections
33.RecruitingRhVEGF (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
Condition: Diabetic Foot
34.RecruitingRituximab/Fludarabine/Cyclophosphamide (FCR) versus Fludarabine/Cyclophosphamide (FC) Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
35.No longer recruitingSafety & Efficacy Study of rhuFab V2 in Combination with Verteporfin for treatment of Age-related Macular Degeneration
Condition: Age-Related Maculopathy
36.RecruitingSafety and Efficacy Study of Nutropin AQ to Treat Growth Restriction in Children with Cystic Fibrosis
Condition: Cystic Fibrosis
37.No longer recruitingSafety and Efficacy Study of Omnitarg (Pertuzumab) to Treat Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
38.No longer recruitingSafety and Efficacy Study of rhuFAb V2 (Ranibizumab) to Treat Age-Related Macular Degeneration
Condition: Age-Related Maculopathy
39.RecruitingSafety and Efficacy Study of Rituximab Compared with Placebo in Adults with Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
40.RecruitingA Safety and Efficacy Study of Xolair in Peanut Allergy
Condition: Allergy
41.RecruitingA Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate
Condition: Rheumatoid Arthritis
42.No longer recruitingSafety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Condition: Neoplasms
43.No longer recruitingSafety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Condition: Colorectal Cancer
44.No longer recruitingA study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies
Condition: Peripheral Neuropathy
45.RecruitingStudy to evaluate the safety and effect of pertuzumab in patients with advanced non-small cell lung cancer, which has progressed after prior chemotherapy
Condition: Non-small cell lung cancer
46.No longer recruitingA Study to Evaluate the Safety and Effect of Pertuzumab on Cancerous Lesions in Women with Advanced, Refractory or Recurrent Ovarian Cancer
Condition: Ovarian Cancer
47.RecruitingTreatment of HER2-Positive Metastatic Breast Cancer with Herceptin and Bevacizumab (antibodies against HER2 and VEGF)
Condition: Breast Cancer
48.SuspendedTrial of Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer in Previously Treated Patients
Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act